Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07222748 · ClinicalTrials.gov registry record · Phase 3
A Study of TLC590 for Postsurgical Pain Following Bunionectomy
A Phase 3 study of Postoperative Pain, sponsored by TLC Biopharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 4
- Study locations
NCT07222748: Recruiting Phase 3 study of Postoperative Pain, sponsored by TLC Biopharmaceuticals.
NCT07222748 is a Phase 3 study of Postoperative Pain that is actively recruiting participants, run by TLC Biopharmaceuticals. The registered enrollment target is 300 participants, above the 229-participant average among 120 other Postoperative Pain trials with a reported enrollment target (31% higher). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07222748, a Phase 3 study of Postoperative Pain, is actively recruiting participants, sponsored by TLC Biopharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a Phase 3, randomized, double-blind, comparator- and placebo-controlled study to evaluate analgesic efficacy and safety of TLC590 via local infiltration in adult subjects following bunionectomy.
Primary Outcome
Pain intensity is measured using an 11-point Numeric Rating Scale (NRS) (0-10), where 0 represents "no pain" and 10 represents "worst pain imaginable", and higher scores indicate worse pain.
Conditions Studied
Interventions
- DRUG Saline Placebo
- DRUG TLC590
- DRUG Liposomal Bupivacaine
Study Locations (4)
Texas
- First Surgical Hospital - Bellaire
- Memorial Hermann Village - Houston
- Endeavor Clinical Trials - San Antonio
Florida
- Clinical Pharmacology of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2025-11-17 |
| Est. Completion | 2026-05 |
| Phase | Phase 3 |
What NCT07222748 shows while recruiting
NCT07222748 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 229-participant average among 120 other Postoperative Pain trials with a reported enrollment target (31% higher).
The record links to 1 condition, with Postoperative Pain appearing as the primary indexed condition, and to 3 interventions - of which Saline Placebo is the first listed.
NCT07222748 reports a single indexed study location in Texas, Florida.
Frequently Asked Questions
What is clinical trial NCT07222748 about?
NCT07222748 is a clinical study titled "A Study of TLC590 for Postsurgical Pain Following Bunionectomy". This is a Phase 3, randomized, double-blind, comparator- and placebo-controlled study to evaluate analgesic efficacy and safety of TLC590 via local infiltration in adult subjects following bunionectomy.
What is the current status of trial NCT07222748?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2025-11-17. Estimated completion is 2026-05.
What conditions does trial NCT07222748 study?
This clinical trial studies the following conditions: Postoperative Pain.
What interventions are being tested in trial NCT07222748?
The interventions under investigation include: Saline Placebo (DRUG), TLC590 (DRUG), Liposomal Bupivacaine (DRUG).
Who is sponsoring clinical trial NCT07222748?
This trial is sponsored by TLC Biopharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07222748 being conducted?
This trial has 4 study locations across Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postoperative Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07222748's enrollment target sits among peer trials
300 20th of 120 higher than 101 of 120 other Postoperative Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Postoperative Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Trial of Intravenous Lidocaine After Spinal Surgery to Prevent Delirium and Reduce Pain
RECRUITING · Phase 3
-
RADA16 for Adult Tonsillectomy
RECRUITING · Phase 3
-
Methadone in TKA for Post-op Pain and Opioid Reduction
RECRUITING · Phase 3
-
Methadone in THA for Post-op Pain and Opioid Reduction
RECRUITING · Phase 3
-
Perioperative Lidocaine and Ketamine in Abdominal Surgery
ACTIVE NOT RECRUITING · Phase 3
-
Comparison of the Safety of Q8003 Versus Morphine Equivalent Doses of Its Components (Oxycodone and Morphine) in Bunionectomy Patients
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI